Brokerages Set Evolent Health, Inc. (NYSE:EVH) Price Target at $25.90

Evolent Health, Inc. (NYSE:EVH) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $26.18.

EVH has been the topic of a number of analyst reports. Citigroup reduced their price objective on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Truist Financial reissued a “buy” rating and set a $33.00 price target on shares of Evolent Health in a research report on Tuesday, August 27th. Barclays cut their price objective on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. BTIG Research decreased their target price on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Stephens downgraded shares of Evolent Health from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $38.00 to $16.00 in a report on Friday, November 8th.

Institutional Investors Weigh In On Evolent Health

Several institutional investors and hedge funds have recently modified their holdings of EVH. Covestor Ltd lifted its position in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC increased its stake in Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after buying an additional 1,556 shares during the period. Quarry LP acquired a new stake in Evolent Health during the 2nd quarter worth approximately $32,000. Canada Pension Plan Investment Board purchased a new position in Evolent Health in the 2nd quarter valued at approximately $61,000. Finally, Quest Partners LLC acquired a new position in shares of Evolent Health in the second quarter worth $87,000.

Evolent Health Trading Down 7.9 %

EVH opened at $11.71 on Friday. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -12.87 and a beta of 1.45. The company’s 50 day simple moving average is $21.12 and its two-hundred day simple moving average is $23.26. Evolent Health has a 1-year low of $11.17 and a 1-year high of $35.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.